{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:16Z","timestamp":1761093016813,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.urolonc.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T09:05:28Z","timestamp":1456909528000},"page":"368-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Approaches to minimize castration in the treatment of advanced prostate cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Kreshnik","family":"Zejnullahu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Arevalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.02.001_bib1","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen deprivation therapy predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"23","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.02.001_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.02.001_bib5","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib6","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib7","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2016.02.001_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2016.02.001_bib9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen deprivation therapy in men with prostate cancer","volume":"33","author":"O\u05f3Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.7326\/0003-4819-158-10-201305210-00005","article-title":"Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer","volume":"158","author":"Daskivich","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2016.02.001_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.juro.2007.08.133","article-title":"The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy","volume":"179","author":"Makarov","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.02.001_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2016.02.001_bib14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2005.02.111","article-title":"Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer","volume":"23","author":"Zelefsky","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib15","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.juro.2008.03.138","article-title":"Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy","volume":"179","author":"Moul","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib16","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1200\/JCO.2005.03.5311","article-title":"Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate","volume":"23","author":"Ryan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.urolonc.2016.02.001_bib17","article-title":"TROG 03.06 and VCOG PR 01-03: the Timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD) collaborative randomised phase III trial","volume":"33","author":"Duchesne","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0960-0760(96)00018-0","article-title":"Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model","volume":"58","author":"Sato","year":"1996","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib19","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Urooncological Group","volume":"55","author":"Calais da Silva","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib20","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2012.01.122","article-title":"The FinnProstate study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer","volume":"187","author":"Salonen","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","article-title":"Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomized phase 3 study by the South European Urooncological Group","volume":"66","author":"Calais da Silva","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urolonc.2011.03.008","article-title":"Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer","volume":"31","author":"Langenhuijsen","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib23","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2012.11120.x","article-title":"Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial","volume":"110","author":"Mottet","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.02.001_bib24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.urolonc.2016.02.001_bib25","article-title":"Long-term consequences of intermittent and continuous androgen deprivation in older patients with metastatic prostate cancer","volume":"33","author":"Hershman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2016.02.001_bib27","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","article-title":"Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup","volume":"164","author":"Iversen","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib28","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.1999.17.7.2027","article-title":"Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project Study","volume":"17","author":"Boccardo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib29","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib30","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.26732","article-title":"Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782","volume":"118","author":"Monk","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.02.001_bib31","first-page":"149","article-title":"Novel mutations of the androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.02.001_bib32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2016.02.001_bib33","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.02.001_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-na\u00efve prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib36","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/pros.22504","article-title":"Adaptive auto-regulation of androgen receptor provides a paradigm-shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer","volume":"72","author":"Isaacs","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.02.001_bib37","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Science Transl Med"},{"key":"10.1016\/j.urolonc.2016.02.001_bib38","article-title":"Antigen-specific immune responses through 24 months in the STAND trial: a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC)","volume":"33","author":"Antonarakis","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib39","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.02.001_bib40","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.juro.2008.07.048","article-title":"Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, and cellular immunotherapy","volume":"180","author":"Urba","year":"2008","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391600034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391600034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:08:41Z","timestamp":1761041321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814391600034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S107814391600034X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.02.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approaches to minimize castration in the treatment of advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}